<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001915'>Aplastic anemia</z:hpo> is a rare <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> disorder </plain></SENT>
<SENT sid="1" pm="."><plain>Allogeneic hematopoietic cell transplantation (alloHCT) and immunosuppressive therapy (IST) are the main therapeutic modalities currently used to treat patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Systematic reviews and meta-analyses of randomized controlled trials (RCTs) are regarded as the highest level of evidence and as such aid practitioners in solving clinical questions </plain></SENT>
<SENT sid="3" pm="."><plain>The objective of this review is to assess the base of evidence for the common practice and the current guidelines for the management of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>It focuses on data obtained from systematic reviews and meta-analyses of RCTs conducted in this field </plain></SENT>
<SENT sid="5" pm="."><plain>Specifically, it focuses on four major therapeutic questions: the roles of alloHCT, IST, hematopoietic growth factors and supportive care </plain></SENT>
</text></document>